Posting of EGM Notice and Explanatory Memorandum
Wellnex Life Limited
07 August 2026
ASX/AIM Announcement
7 August 2026
Posting of the Notice of Extraordinary General Meeting and Explanatory Memorandum
Wellnex Life Limited (ASX/AIM: WNX) (the "Company") announces that, further to the Company's announcement on 6 August 2026, the Notice of Extraordinary General Meeting ("EGM") and explanatory memorandum has been posted to shareholders.
The EGM will be held at Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000 Australia, at 10:00 am AEST (1:00 am BST) on 8 September 2026. The purpose of the EGM is for the Company to seek the necessary shareholder approval required in connection with the Company's proposed sale and disposal of the Pain Away Business to Mentholatum Australasia Pty Ltd for the purposes of Rule 15 of the AIM Rules, and all other purposes.
Copies of the Notice of EGM and explanatory memorandum are available from the Company's website: https://wellnexlife.investorportal.com.au/
Capitalised terms used but not defined in this announcement will have the same meaning given to them in the Notice of EGM and explanatory memorandum.
This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).
--- END ---
For further information, please contact:
Wellnex Life Limited (ASX/AIM:WNX)
Eric Jiang
Interim Executive Chairman
UK Investors
Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494
Orana Corporate LLP (Joint Broker) swykeham@oranacorp.com
Sebastian Wykeham
S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470
David Hignell / Vadim Alexandre
To learn more, please visit: https://wellnexlife.com.au/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.